μM	Relative EV71 Viral Load		
0.31	6.24	6.73	6.28
0.63	6.68	6.50	6.99
1.25	6.53	6.02	6.59
2.50	6.00	5.61	ND
5.00	4.98	3.91	4.77
10.00	3.59	0.00	0.00
20.00	0.00	0.00	0.00




FIG. 1



log10 TCID50/ml
9
8
7
6
5
4
3
2
1
0
EC50=4.7µM
0
10
20
30
40
50
µM

FIG. 2



PFU /ml
500 000
400 000
300 000
200 000
100 000
0
EC50=2.6µM
0
10
20
30
40
µM

FIG. 3



6
5
4
3
2
1
0
log10 TCID50/ml
EC50=8.07μM
1
2
4
8
16
32
μM

FIG. 4



12,000,000
10,000,000
8,000,000
6,000,000
4,000,000
2,000,000
0
PFU /ml
EC50=2.0μM
0.5
1
2
4
8
16
32
μM

FIG. 5



10
8
6
4
2
0
log10 TCID50/ml
2.5
5
10
20
40
μM

FIG. 6



30
20
10
0
EV71 Viral Load
(EV71 RNA/GAPDH RNA)
0mg/kg
50mg/kg
mock

FIG. 7



CVA16 Viral Load
(CVA16 RNA/GAPDH RNA)
4096
1024
256
64
16
4
1
No. 1
No. 2
Brain
Bone marrow
Heart
Small intestine
Kidney
Liver
Lung
Muscle
Spleen
Thymus
Serum

FIG. 8



CVA16 Viral Load
(CVA16 RNA/GAPDH RNA)
2000
1500
1000
500
0
Infection group
Drug group
Placebo group
Brain
Bone marrow
Muscle
Serum

FIG. 9



Cellular ATP Levels
(% of the control cells)
150
120
90
60
30
0
10^{-6}
10^{-5}
10^{-4}
10^{-3}
10^{-2}
10^{-1}
10^{0}
10^{1}
10^{2}
10^{3}
10^{4}
μM

FIG. 10



Number of mice
8
6
4
2
0
Control
20mg/kkg
50mg/kg
0 1 2 3 4 5 6 7 8 9 10 11
Post-injection time

FIG. 11



Relative EV71 Viral Load
(log10 TCID50/ml)
Cells not pre-treated with drug
Cells pre-treated with drug
7
6
5
4
3
A
B
C
D
E
F
Prior to infection + + - - -
During infection + + + + -
Post-infection + - - + +

FIG. 12



Relative EV71 Viral Load
log10 TCID50/ml
Cell viability
(% of the negative control)
Relative EV71 viral load
Cell viability
8
6
4
2
0
100
80
60
40
20
0
1
2
4
8
16
32
64
μM

FIG. 13




FIG. 14

μM	10-fold reduction	100-fold reduction
SH-TS	7.14	25.35
SH-RS	4.41	16.29





FIG. 15



μM	SH-TS	SH-RS
EC_{50}	2.24	3.47

FIG. 16




FIG. 17



EV71 copies/ml in serum
400
300
200
100
0
0
5
10
15
Day post-infection
Control group
Drug group

FIG. 18



Body Temperature ℃
40.5
40.0
39.5
39.0
38.5
Day Post Infection
control
drug

FIG. 19



NF 279
Relative EV71 Viral Load
(log10 TCID50/ml)
Cell viability
RNA
Cell viability
Log10 μM
0
1
2
3
4
5
6
7
0
20
40
60
80
100
120
1.0
1.2
1.4
1.6
1.8
2.0

FIG. 20




FIG. 20 (Continued)




FIG. 20 (Continued)




FIG. 20 (Continued)




FIG. 20 (Continued)




FIG. 20 (Continued)



NF110
log10 relative EV71 titer
Viability
μM
0.1
1
10
100
0
1
2
3
4
5
6
7
0
20
40
60
80
100
120
log10 EV71 relative titter
viability
viability 0505

FIG. 21




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)

A 740003




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)




FIG. 21
(Continued)